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To the Editor:
We read with great interest a recent
meta-analysis by Yan and associates1
of randomized and norandomized stud-
ies of percutaneous coronary interven-
tion with drug-eluting stents (DESs)y among patients with multivessel disease assigned to
ass grafting (CABG). Asterisk indicates that the stu
l disease; 3VD, triple-vessel disease; CARDia, Coron
ntervention with Taxus and Cardiac Surgery trial.5
of Thoracic and Cardiovascular Surgeversus coronary artery bypass grafting
(CABG) for coronary artery disease,
including not only multivessel disease
(MVD) but also single-vessel disease
or left main coronary artery disease.
This meta-analysis,1 as well as a previ-
ous meta-analysis of MVD,2 demon-
strated no difference in all-cause
mortality at least 1 year after DES and
CABG treatments. Although thesepercutaneous coronary intervention (PCI) with
dy provided an adjusted odds ratio. IV, Inverse
ary Artery Revascularization in Diabetes trial4;
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Letters to the Editormeta-analyses1,2 included nonrandom-
ized observational studies, data of
unadjusted crude mortality were
abstracted and combined. In contrast,
our preliminary meta-analysis3 of
adjusted risk estimates from non-
randomized studies have suggested
that DES use may increase mortality
at 1 year or more relative to CABG
for MVD. To assess whether DES
treatment for MVD increases follow-
up mortality relative to CABG, we up-
dated our previous meta-analysis,3
combining not unadjusted but adjusted
risk estimates.
Studies considered for inclusionmet
the following criteria: the design was
a comparative study (randomized con-
trolled trial or nonrandomized obser-
vational study); the study population
was limited to patients with MVD; pa-
tients were assigned to DES or CABG
treatment; and main outcomes in-
cluded adjusted (in case of observa-
tional studies) hazard ratios (HRs), or
odds ratios if HRs were unavailable,
for all-cause mortality at 1 year and
beyond. Our comprehensive search
(current through January 2011) identi-
fied 2 randomized trials4,5 and 11
nonrandomized studies. We included
2 randomized trials (Coronary Artery
Revascularization in Diabetes trial
[CARDia]4 and Synergy between Per-
cutaneous Coronary Intervention with
Taxus and Cardiac Surgery trial [SYN-
TAX ]5), although they included com-
plex single-vessel disease (6.9%) and
left main coronary artery disease with-
out MVD (12.7%), respectively. We
abstracted 2 unadjusted HRs from ran-
domized trials and 18 adjusted HRs
and 1 adjusted odds ratio from non-
randomized studies. Pooled analysis
of all the 21 risk estimates demon-
strated a statistically significant 24%
increment in mortality with DES
treatment relative to CABG in a ran-
dom-effects model (HR, 1.24; 95%
confidence interval, 1.02–1.50; P ¼
.03; Figure 1). There was significant
between-study heterogeneity (P ¼
.003) but little difference in the pooled
result from fixed-effects modeling242 The Journal of Thoracic and C(HR, 1.25; 95% confidence interval,
1.12–1.39; P< .0001). When 7 HRs
in double-vessel disease and 8 HRs in
triple-vessel diseasewere pooled sepa-
rately, DES treatment was associated
with, respectively, a statistically non-
significant 27% and a 36% increment
in mortality relative to CABG. Elimi-
nating the 2 randomized trials4,5 that
included a few with single-vessel
disease or left main coronary artery
disease without MVD did not substan-
tially change the pooled point estimate
(random-effects HR, 1.25; 95% confi-
dence interval, 1.005–1.55; P ¼ .045).
There was no evidence of significant
publication bias (P ¼ .88 by an
adjusted rank-correlation test, P ¼ .96
by a linear regression test).
Despite the results of the previous
unadjusted meta-analyses, including
that of Yan and collaborators,1,2 we
found our current adjusted meta-
analysis of mainly nonrandomized
observational studies with a few ran-
domized controlled trials to indicate
that DES treatment for MVD may in-
crease all-cause mortality at 1 year
and beyond by 24% relative to
CABG. CABG rather than DES treat-
ment should therefore be considered
for MVD, because follow-up mortal-
ity reduction must imply the greatest
clinical benefit among patients with
MVD. To cut the Gordian knot of
DES versus CABG for MVD, how-
ever, additional randomized trials are
needed.
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We congratulate Takagi and col-
leagues on their updated meta-
analysis comparing drug-eluting stent
(DES) treatment with coronary artery
bypass grafting (CABG) for patients
with multivessel coronary artery dis-
ease. Our meta-analysis of trials
(1 randomized, 24 nonrandomized)
comparing CABGwith DES treatment
for multivessel coronary artery disease
showed similar rates of all-cause mor-
tality in the 2 groups but a lower inci-
dence of major adverse cardiac and
cerebrovascular events in the CABG
group at 1 year and beyond.1 Themajor
contributor to the increased incidence
of major adverse cardiac and cerebro-
vascular events seen in the DES group
was the increased rate of repeat revas-
cularization in that group.
Unlike our meta-analysis, in which
unadjusted hazard ratios from the ob-
servational studies were used, Takagi
and colleagues’ analysis used adjusted
hazard ratios to demonstrate signifi-
cantly increased mortality in the
DES group beyond 1 year. When trials
including patients with 2-vessel dis-
ease and 3-vessel disease were pooled
separately, no significant difference in
mortality was seen.
These studies provide further evi-
dence that CABG remains the stan-
dard of care for patients with
multivessel coronary artery disease.
In the 3-year outcomes of the Synergy
